Sanofi (SNY) Cost of Revenue (2009 - 2026)

Sanofi has disclosed Cost of Revenue across 18 years of filings, most recently posting $3.5 billion for Q2 2026.

• In Q2 2026, Cost of Revenue rose 3.54% year-over-year to $3.5 billion; the TTM figure through Jun 2026 stood at $33.2 billion (up 35.32% YoY), while the FY2025 annual figure was $15.2 billion, up 6.28% from the prior year.
• Cost of Revenue came in at $3.5 billion for Q2 2026 at Sanofi, down from $3.7 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $15.2 billion in Q4 2025 to a low of $3.0 billion in Q1 2025.
• Average Cost of Revenue over 5 years is $6.2 billion, with a median of $3.6 billion recorded in 2026.
• Year-over-year, Cost of Revenue slipped 13.53% in 2022 and jumped 170.06% in 2025.
• Over 5 years, Cost of Revenue stood at $12.1 billion in 2022, then climbed by 12.08% to $13.6 billion in 2023, then advanced by 3.86% to $14.1 billion in 2024, then grew by 7.65% to $15.2 billion in 2025, then slumped by 76.91% to $3.5 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $3.5 billion in Q2 2026, $3.7 billion in Q1 2026, and $15.2 billion in Q4 2025.